Guiyang Xintian Pharmaceutical (002873.SZ) mainly engages in drugs for gynecological and urological diseases.
Guiyang Xintian Pharmaceutical (002873.SZ) stated on the investor interaction platform on August 12 that as a national high-tech enterprise focused on the research and development, production and sales of new Chinese patent medicines, the company has been deeply cultivating the Chinese patent medicine market since its establishment. It mainly engages in the research and development, production and sales of Chinese patent medicine products for gynecology, urology diseases, and also covers fields such as oral, breast thyroid, antipyretics, heat-clearing, blood supplementing, cardiovascular diseases and anti-tumor treatment.
Guiyang Xintian Pharmaceutical Co.,Ltd.'s (SZSE:002873) Shareholders Might Be Looking For Exit
Guiyang Xintian Pharmaceutical (002873.SZ): With the advancement of a series of reform measures, the company's business has emerged from a low period.
On July 29th, Gelunhui reported that Guizhou Xintian Pharmaceutical (002873.SZ) stated during an investor relations activity that the company launched a "cost reduction and efficiency enhancement" reform of the R&D, production and sales system at the end of 2022 due to changes in the industry environment, among other factors. In multiple dimensions and levels, the goal was to control costs and improve operational efficiency in order to seek long-term, healthy, stable, and sustainable development for the company. After more than a year, the company's entire "cost reduction and efficiency enhancement" reform has been basically completed, and various new operating systems and management models have begun to operate normally and gradually optimized, and some phased reform achievements have also been presented. Currently,
Guiyang Xintian Pharmaceutical (002873.SZ): Termination of Issuance of Shares for Acquisition of Assets and Related Transactions.
On July 26th, Gelunhui reported that Guiyang Xintian Pharmaceutical (002873.SZ) held the 25th meeting of the 7th Board of Directors and the 17th meeting of the 7th Supervisory Board on July 26, 2024, and approved the proposal to terminate the issuance of shares to purchase assets and related transactions, agreeing to terminate the issuance of shares to purchase assets and related transactions. Since the planning and initial announcement of the transaction, the Company has actively organized the parties involved in the transaction to promote the relevant work of the transaction in strict accordance with the requirements of relevant laws, regulations, and normative documents. Due to different expectations of the parties involved in the transaction, the company and some of the parties involved decided not to proceed with the transaction.
Guiyang Xintian Pharmaceutical (002873.SZ): As of July 19, 2024, the number of shareholders in the company is 19,407.
On July 22, Gelunhui reported that as of July 19, 2024, Guiyang Xintian Pharmaceutical (002873.SZ) had 19,407 shareholders on its investor platform.
List of unrestricted A-share stocks by Zhittong | June 28th.
On June 28th, a total of 22 listed companies had their restricted stocks unlocked, with a total market value of approximately 10.691 billion yuan. The specific unlocking situations for each stock are as follows: Stock Abbreviation (Code) Type of Restricted Stocks Amount Unlocked Xiamen ITG Group Corp., Ltd. (600755) Extended Locked-Up Shares 75.3714 million AVIC Heavy Machinery Co., Ltd. (600765) Stock-Based Incentive 1.8722 million Shenzhen Dawei Innovation Technology Co., Ltd. (002213) Newly Issued A-shares for Institutional Placement 30 million Visionox Technology Inc. (002387) Stock-Based Incentive 0.445 million Shenzhen Kstar Science & Technology Co., Ltd. (002518) Stock-Based Incentive 1.7723 million
Market Might Still Lack Some Conviction On Guiyang Xintian Pharmaceutical Co.,Ltd. (SZSE:002873) Even After 45% Share Price Boost
